Consonance Capital Partners
VC Fund
New York, United States
Consonance Capital Partners is a VC fund in New York focused on Biotechnology and Health Care. Consonance Capital is a healthcare investment firm that invests broadly across the healthcare landscape. Public investments are made under the direction of Consonance Capital Management (“CCM”), a long/short public equity manager. Private investments, which include growth equity, leveraged buyouts, and recapitalizations, are made under thedirection of Consonance Capital Partners (“CCP”), a private equity manager. CCM and CCP operate in a collaborative fashion. Consonance Capital was established in 2005 and is located in New York City.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 40%
- Fund size:
- $856M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Consonance Capital Partners invests in
Stages Consonance Capital Partners invests in
Countries Consonance Capital Partners invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Biotechnology 6 (60%)
- Health Care 5 (50%)
- Therapeutics 5 (50%)
- Medical 4 (40%)
- Pharmaceutical 2 (20%)
Stage
- Post-IPO Equity 3 (30%)
- Private Equity 2 (20%)
- Pre-Seed 1 (10%)
- Series A 1 (10%)
- Funding Round 1 (10%)
Country
- United States 6 (60%)
- Canada 1 (10%)
- Nigeria 1 (10%)
- United Kingdom 1 (10%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Charlie Kolisek
Vice President
|
Vice President | Total investments: 0 | Find email | |
| CFO | Total investments: 0 | Find email | ||
Mitchell Blutt
Managing Partner and Co-Founder
|
Managing Partner and Co-Founder | Total investments: 1 | Find email | |
Nancy-Ann DeParle
Partner
|
Partner | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Civic Eagle develops software that helps companies discover and analyze legislation and regulations with no manual work. Civic Eagle's platform searches, tracks, and works with legislations across the country and does the discovery work so that policy advocates can focus on winning campaigns, thereby enabling clients to promote betterdemocratic outcomes for people and their communities.The company was founded in 2015 and is headquartered in Minneapolis, Minnesota. | $10M / Series A / May 11, 2022 | ||
| Surrozen is a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. Surrozen is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with potential application across multiple disease areas, including diseases of the intestine, liver, retina,cornea, lung, kidney, cochlea, skin, pancreas and central nervous system. | $120M / Post-IPO Equity / Aug 12, 2021 | ||
| PayHippo is making it easier to finance small and medium sized businesses in Africa. There is a need for financing of $158 bn for SMEs in Nigeria alone. To start, PayHippo helps SMEs access and spend lender capital effectively. During their first full operational year in 2020, the PayHippo co--founders leveraged their domain expertise and foundingexperience to beat their 2020 goal by 50%. | $1.1M / Pre-Seed / Jul 01, 2021 | ||
| Silence Therapeutics plc is a United Kingdom-based ribonucleic acid (RNA) technology company. The Company is primarily involved in the research and development of pharmaceutical products. The Company's technology harnesses the body's natural mechanisms to create therapeutic effects within its own cells. The Company has a has a genetictoolkit with its own therapeutic payloads to modulate gene expression up as well as down in preclinical in vivo models, and delivery systems for various organs and cell types. | $45.5M / Post-IPO Equity / Feb 18, 2021 | ||
| Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, developing antibody therapeutics to treat both solid tumors and hematologic malignancies. Compass is leveraging its proprietary StitchMabs™ and common light-chain enabled multispecific platforms to empirically identify multispecifics and combinations of antibody therapeuticsthat can be advanced to the clinic. The company's lead product candidate, CTX-009, is a bispecific antibody, which inhibits both DLL4-mediated Notch signaling and VEGF-A signaling. CTX-009 has completed a Phase 1 dose escalation study and is in a Phase 1b study in combination with chemotherapy in patients with solid tumors. The company’s second product candidate, CTX-471, is a novel agonistic antibody of CD137, a co-stimulatory receptor on immune cells. It is currently being evaluated in a Phase 1b study in patients who were previously treated with PD-1/PD-L1 checkpoint inhibitors, and who subsequently relapsed or progressed after a period of stable disease. Compass’ third product candidate, CTX-8371, is a bispecific antibody that blocks both PD-1 and PD-L1 and is in IND-enabling studies. The company was founded in 2014 and is headquartered in Boston, Massachusetts. | $60.5M / Jun 23, 2020 | ||
| Mersana Therapeutics employs its biodegradable polymer platform to create new and better medicines. They are advancing their own clinical-stage pipeline of novel compounds with the potential to address multiple oncology indications. It was founded in 2005 and headquartered in Cambridge, Massachusetts. | $65M / Post-IPO Equity / Apr 07, 2020 | ||
| Bako Diagnostics is a healthcare services company that provides diagnostic and therapeutic services. They specialise in anatomic pathology, nail DNA testing, ENFD, bacteriology, and mycology. They are committed to the advancement of podiatric dermatology through education, research, and financial support that no other national lab or pathologygroup can match. | Private Equity / Jan 07, 2016 | ||
| Telesta Therapeutics is a biopharmaceutical company focused on the development, manufacturing and commercialization of transformative human therapeutics. Our main focus is on novel medicines that address major unmet medical needs, particularly in oncology. Our anchor product, MCNA, has completed a Phase III pivotal study in patients with non-muscleinvasive bladder cancer that have failed the first line therapy, bacillus Calmette-Guérin (BCG). Telesta submitted a Biologics Licensing Application (BLA) for MCNA with the U.S. FDA on June 29, 2015 and is seeking, upon marketing approval in the U.S., to make MCNA available for patients and their physicians. Our ultimate goal is to transform the treatment landscape and prolong and improve the lives of those affected by bladder cancer, one of the most common types of cancers today. | $28.6M / Venture - Series Unknown / Aug 20, 2015 | ||
| Enclara Pharmacia offers clinical services, operation processes, and educational programs to improve patient care. | Private Equity / Mar 01, 2014 | ||
| See all 10 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Consonance Capital Partners invest in?
Consonance Capital Partners invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Post-IPO Equity and Private Equity stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Consonance Capital Partners?
Public channels for Consonance Capital Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Consonance Capital Partners?
The team at Consonance Capital Partners includes Charlie Kolisek (Vice President), Gabriela J. Franco-Boland (CFO) and Mitchell Blutt (Managing Partner and Co-Founder). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
